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DNA barcoding methods originally developed for the identification of plant specimens have been 
applied to the authentication of herbal drug materials for industrial quality assurance. These methods 
are intended to be complementary to current morphological and chemical methods of identification. 
The adoption of these methods by industry will be accelerated by the introduction of DNA based 
identification techniques into regulatory standards and monographs. The introduction of DNA 
methods into the British Pharmacopoeia is described, along with a reference standard for use as a 
positive control for DNA extraction and PCR. A general troubleshooting chart is provided to guide 
the user through the problems that may be encountered during this process. Nevertheless, the nature of 
the plant materials and the demands of industrial quality control procedures mean that conventional 
DNA barcoding is not the method of choice for industrial quality control. The design of DNA 
barcode-targeted qPCR and High Resolution Melt Curve (HRM) tests is one strategy for developing 
rapid, robust, reliable protocols for high-throughput screening of raw materials. The development of 
authentication tests for wild-harvested Rhodiola rosea L. is used as a case study to exemplify these 
relatively simple tests. By way of contrast, the application of Next Generation Sequencing (NGS) to 
create a complete profile of all the biological entities in a mixed herbal drug is described and its 
potential for industrial quality assurance discussed.  
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Introduction 
There has been growing interest in the use of DNA-based methods for the identification of medicinal 
plants and authentication of herbal products. Several recent reviews have provided a comprehensive 
overview of the background literature to DNA barcoding [1,2], DNA technologies [3], authentication 
tests [4,5] and the detection of adulteration in commercial products [1,3,5]. This review focuses on the 
practical implications of incorporating DNA tests into the quality assurance procedures of the herbals 
industry. A major aim is to give practical guidance on the implementation of DNA tests in terms of 
infrastructure and procedures, data analysis and troubleshooting, by way of selected case studies. It 
also provides confirmation that, despite the recent controversy around the mis-application of DNA 
authentication methods to processed herbal products [6,7], DNA based technology is a valuable 
addition to the toolkit of industrial quality assurance. 
Quality assurance of herbal medicinal products 
The medicinal status and regulation of herbal medicines varies considerably in different parts of the 
world [8–10]. In some countries such as the US, all herbal products are treated as food supplements 
[11,12], whilst elsewhere they are considered to be medicines, or are treated as a distinct category of 
medicinal product [8,13]. It is also still the case that many countries lack a regulatory framework to 
control the quality and safety of herbal products [8].  
This review will focus on the regulation of herbal medicines in the European Union. Legislation in the 
European Union (EU) recognises three categories of herbal product:  
Well-established herbal medicinal products (HMPs) are regulated by Directive 2001/83/EC and 
subsequent amendments. This requires that all medicinal products (including HMPs) can be marketed 
in the EU only when they have obtained a Marketing Authorisation. Authorisation is dependent on the 
specification of pharmaceutical quality, safety and efficacy information, along with the medicinal 
product name, pharmaceutical form, indication, dosage and risk information [14].  
The Traditional Herbal Medicines Directive 2004/24/EC amendment to Directive 2001/83/EC aimed 
to simplify the procedure for traditional herbal medicines (THMs) by allowing for Registration of 
THMs shown to have been used traditionally for 30 years including at least 15 years within the EU 
[8,15]. It also requires that safety data is provided, though this can be literature based, and that the 
producer can guarantee the quality of their product with reference to Good Manufacturing Process 
(GMP) [10,15,16] and the WHO Good Agricultural and Collection Practices for Medicinal Plants 
which spell out requirements for species identification, collection practices and cultivation of 
medicinal plant species [17]. The claims on the labels of medicinal plant products also fall under this 
legislation, and will become standardised for therapeutic claims and safety information [14,15].  
Thus, herbal medicinal products can be sold in the EU either with a Marketing Authorisation or with 
THM Registration. Marketing authorisations require, amongst other measures, that the product be 
proven to be efficacious. This can either be shown in new clinical trials for safety and efficacy, or via 
a ‘bibliographic application’ in which the active compound of the medicinal plant in question can be 
shown to have been well established in the EU for 10 years [14,15]. If the therapeutic efficacy of a 
herbal preparation is not fully proven, a THMP registration may be obtained. This requires that the 
product proves not to be harmful in the specified conditions of use and the pharmacological effects or 
efficacy are plausible on the basis of long-standing use and experience [14].  
A complex boundary exists between herbal medicines and food supplements (botanicals), which are 
regulated by the European Food Standards Authority (EFSA) under The Food Supplements Directive 
(2002/46/EC) [12,14]. A herbal medicine is defined as a medicinal product intended for treating or 
preventing disease. In contrast, a food supplement is described as a product designed to supplement 
the normal diet which is a concentrated source of a substance(s) with a nutritional or physiological 
effect and is sold in dose form. The main distinction between these two definitions is that only 
medicinal products can claim to be used for the treatment and prevention of disease. However, it is 
possible that the same substance could be sold under either scheme, depending on whether the 
producer wishes to make a health claim for the product. These definitions refer only to EU 
regulations, and differ in other jurisdictions, presenting a difficult challenge for harmonisation of 
herbal product quality and safety regulation [11,12,18].  
One of the key requirements of herbal medicine Market Authorisation or THM Registration is that the 
quality standards are defined. For well-established medicines, the quality standards are detailed in 
monographs of the European Pharmacopoeia (Ph.Eur) under the aegis of the European Directorate for 
the Quality of Medicines and HealthCare (EDQM). Monographs for registered THMPs are gradually 
being incorporated into the Ph.Eur. The Committee on Herbal Medicinal Products (HMPC) of the 
European Medicines Agency (EMA) produces Community herbal monographs for THMPs that 
contain safety data but not quality standards [11].  
Herbal products described in a Ph.Eur monographs must be prepared in accordance with the published 
quality standards. These prescribe benchmarks for identification and authentication of plant material 
upstream of manufacturing and processing, and standards for purity. These include tests for loss on 
drying, water and total ash content, and pesticide, heavy metal and microbial contamination. Specific 
toxins and radioactive contamination testing may be stipulated in certain circumstances. A test for 
foreign matter is also required. The material is typically sampled and sorted by eye for the presence of 
foreign matter, which is weighed and given as a percentage of the total. The acceptable foreign matter 
threshold is usually set at 2%, i.e. 98% purity, but different levels may be authorised for individual 
products. The authentication of the plant material is generally based on microscopic and macroscopic 
botanical identification, and on simple chemical assays such as HPTLC and HPLC [9,19].  
With regard to herbal food supplements, EFSA has published guidance for the safety assessment of 
botanicals and derived preparations which are intended for use in food supplements [20]. The 
recommendations for identification and product specification are to follow the Ph.Eur standards where 
possible. A compendium of botanicals that have been reported to contain substances that may be of 
health concern when used in food or food supplements has also been published by EFSA and is 
subject to regular updates [21]. 
Introduction of DNA testing into the British Pharmacopoeia 
Within the EU, national bodies are responsible for the implementation of community herbal medicinal 
products regulations. For example, in the UK, the Medicines and Healthcare products Regulatory 
Agency (MHRA) administers the THMP registration scheme and also responsible for production of 
the British Pharmacopoeia (BP). The monographs of the BP are harmonised with the Ph.Eur, but 
additional monographs that are not found in the Ph.Eur may be included in the BP.  
In 2016 the British Pharmacopoeia published a new Appendix method, DNA Based Identification 
Techniques for Herbal Drugs [22]. The method sets out the basic requirements for molecular 
identification that are applicable to any investigation. General procedures are given for DNA 
extraction, PCR, gel electrophoresis, and DNA sequencing and analysis. The second section, now 
listed in a Supplementary Chapter [23], details the steps that are particular to the monograph species. 
For each subject, information is given on DNA purification requirements, PCR primer use, and most 
importantly the reference sequence.  
The initial subject for this identification method was Holy Basil, defined in the monograph as 
Ocimum tenuiflorum L. The first point to be considered was sampling. British Pharmacopoeia 
monographs are elaborated by analysing material that is traded in the UK. This is based on the 
practise for allopathic pharmaceutical drugs that have a specific chemical formula which can be 
directly measured, and industrial production processes. Herbal drugs are less uniform and are ideally 
assessed in their ‘raw’ form, making sample size and variety all the more important. The sampling 
methods and results used in this study are described in more detail in the Supporting Information.  
The next step in the process was barcode region selection. Initially 5 regions were amplified, 
sequenced and assessed for useful sequence variation – variation that distinguished the commercial 
samples from different Ocimum species. The sequence analysis of the plastid trnH-psbA region 
revealed variation that was suitable in terms of both number and size of nucleotide polymorphisms, 
and this result was also informed by published literature [24]. 
Five distinct regions of sequence variation were highlighted as ‘key bases’ for identification using a 
reference sequence (Fig. 1S). Along the length of the ~500bp region, the first three regions are 
between 200 and 250bp (Fig. 2S), and the final two between 300-370bp (Fig. 3S). The key bases were 
selected with care to ensure that repeat regions would not cause false positive matches by ‘anchoring’ 
the regions with non-variable bases at either end. 
The result of this project is a thoroughly tested DNA extraction, purification and amplification method 
for Holy Basil herbal drug material. Further, a reference sequence is published which can be used to 
identify Ocimum tenuiflorum and distinguish it from closely related species known to contaminate 
Holy Basil herbal material. The method and structure that was designed and implemented has formed 
a model for high quality molecular characterisation that can be used with different species. 
Fundamentally, the data generated from the DNA based identification work was used in conjunction 
with results from macroscopic and microscopic analysis, foreign matter testing, loss on drying, acid 
insoluble ash, and HPTLC to ensure that only information from genuine and good quality samples be 
used to produce the benchmarks in the British Pharmacopoeia.  
Introduction of DNA tests into quality control protocols 
The appearance of DNA-based test quality standards indicates that industrial QC laboratories hitherto 
focused on analytical chemistry may need to adapt to the introduction of molecular technologies. The 
next section considers some of the practical issues involved in developing a DNA testing facility 
within an industrial setting.  
When establishing a DNA barcoding facility in existing laboratory space, there are a few simple rules:  
1. Routine molecular biology can co-exist with other analytical techniques – there is no necessity to 
physically separate DNA work from analytical chemistry work, for example.  
2. It is, however, essential to separate some DNA techniques from others. Putting aside a single 
room for all DNA work could be a recipe for disaster.  
The central paradox is that the extraordinary power of PCR (the massive amplification of a small 
number of template molecules) is also its “Achilles heel”. In a routine DNA testing lab, the same few 
barcode amplicons will be generated on an enormous scale. Careless tube opening or pipetting of a 
PCR after thermocycling can generate an aerosol of potential contaminant amplicons. Contamination 
of a new PCR with just a single amplicon from a previous reaction could then generate a cycle of false 
positive results.  
There are several strategies to mitigate DNA contamination of new PCRs, based on the experience of 
forensic and clinical diagnostic PCR laboratories: 
 Separation of “pre-PCR” and “post-PCR” operations in physical space and/or time [25]. A series 
of small clean rooms or compartments are more suitable than a single open laboratory. 
 Establishment of a workflow that ensures that samples and procedures can only move 
downstream from plant material -> DNA extraction -> DNA quantitation -> pre-PCR setup -> 
PCR -> post-PCR analysis -> nested PCR. The most critical backflow to avoid is from post-PCR 
to pre-PCR, e.g. by transfer of amplicons from the “dirty” post-PCR area back into the “clean” 
pre-PCR area [25,26].  
 Where possible, pre-PCR reagents should be dispensed in a separate clean area free from any 
potential template DNA (plant material, genomic DNA and PCR reaction products). It is good 
practice to aliquot reagents such as primers and PCR reagents in this area. 
 Designation of dedicated lab coats, gloves, pipettes and plastic-ware for the pre-PCR areas are 
important elements in the strategy, enforced by training and clear standard operating procedures. 
Most critically, these should spell out the practical issues around movement of personnel and 
materials in and out of the clean area. 
 Procedures for regular decontamination of clean DNA areas should be implemented, by cleaning 
with 10% bleach or commercial DNA destroying cleaners, and/or UV irradiation.  
The positive side is that equipping a routine molecular biology laboratory is relatively inexpensive 
compared to analytical chemistry. A simple PCR facility comprising a conventional PCR machine, gel 
electrophoresis tank plus power supply and a gel imager could cost less than €10,000. A real-time 
PCR machine, especially with high resolution melt curve analysis capability would be more expensive 
€10-25,000. Other specialised equipment to consider include a dedicated spectrophotometer or 
fluorimeter for DNA quantitation, a mechanical homogeniser for tissue disruption and a PCR clean 
hood with air filtration and/or UV irradiation, but these are all relatively inexpensive items.  
A more important consideration is the personnel implications of introducing molecular techniques. 
Whilst the core techniques of DNA barcoding are relatively simple to learn and perform by competent 
technical staff, there is a need for more specialist expertise for troubleshooting poor or unexpected 
results, and in the bioinformatic analysis of results. 
Troubleshooting DNA barcoding methods  
The BP test is based on the standard procedure for DNA barcoding. The limitations of DNA 
barcoding for routine industrial quality testing will be addressed later, but the procedure has particular 
value for the identification of reference specimens and DNA sequences. Fig. 1 shows a typical 
workflow for DNA barcoding. The process starts from DNA extraction of the plant sample, through 
methods for quantitation, PCR and gel electrophoresis, and DNA sequencing. A number of decision 
points are included for quality control and troubleshooting. These cover most eventualities and should 
facilitate the development of routine, reliable protocols. Further guidance on the generic downstream 
processes in Fig. 1 is widely available [27–30]. The upstream steps that are specific to typical raw 
materials for herbal medicines will be briefly considered. 
Plant sample collection for DNA barcoding has been described in detail for taxonomic specimen 
identification [28,31–33]. However, herbal drug material is usually not of this type. Wild harvested 
source materials are typically mature tissues, often roots or rhizomes, that may have been dried slowly 
under poor conditions. In consequence, DNA extraction faces three main challenges: low yield; 
contamination with PCR inhibitory molecules; and DNA degradation [27,28,32]. Low yield is best 
solved by optimising tissue disruption, increasing the proportion of extraction reagent volumes to 
tissue mass and extending the tissue solubilisation time. The effect of contamination by PCR 
inhibitory storage carbohydrates and polyphenolic secondary products can be mitigated by diluting 
the DNA template before PCR, or clean-up of the genomic DNA by alcohol precipitation. Phenolics 
can also be removed by adding polyvinylpolypyrrolidone at an early stage in the extraction [34]. The 
issue of DNA degradation is more problematic. Upstream solutions would involve less damaging 
procedures for drying and processing of the source material. Downstream solutions may employ the 
type of DNA repair and amplification procedures developed for forensic profiling of degraded DNA, 
or target shorter “mini-barcode” regions (see next section) [35–38]. 
If several different types of material are going to be tested, it is advisable to adopt a general-purpose 
extraction method. This will typically be either a commercial kit based on ion exchange mini-
columns, or a variant of the “CTAB” method [39]. A number of comparisons of DNA extractions 
have been carried out, which indicate some variability between commonly used methods and their 
suitability for different tissue types in terms of quantity and quality of DNA extracted [40–42]. 
However, a reliable standard procedure is usually adequate to obtain sufficient DNA for subsequent 
PCR amplification and analysis.  
DNA quantitation is an important indicator of the success of an extraction. Spectrophotometric 
measurement of UV absorbance at 260nm can be used to directly quantify a dsDNA sample. Readings 
at 280nm can indicate residual phenol carryover from the extraction protocol or contamination of the 
extract with phenolic secondary metabolites from the plant material. Absorbance at 230nm may 
indicate carbohydrate contamination, residual guanidinium salts (often used in column based kits) or 
carryover of glycogen used for DNA precipitation [27,30]. However, carbohydrates also absorb at 
260nm, so can interfere with the quantitation of DNA. In contrast, fluorometric methods make use of 
DNA intercalating dyes, so are less susceptible to interference by impurities. There are a number of 
commercial kits available for this purpose, some of which come with a simple dedicated fluorimeter 
with direct calculation of DNA concentration. The DNA is mixed with the reagents and the 
fluorescence compared to reference standards. Fluorescent readings are more specific to double 
stranded DNA, so more reliable particularly at low concentrations, but do not detect the presence of 
contaminants. 
Whilst quantitation gives some indication of the success of an extraction procedure, the ultimate test 
is whether the DNA is amplifiable by PCR. It is therefore common practice to perform a routine DNA 
barcode PCR after extraction to determine whether the DNA is either contaminated or degraded. The 
aim at this stage is to obtain a clear band, not necessarily to determine the sequence of the barcode.  
PCR protocols for plant DNA barcoding have been well described, with specific information about 
the choice of barcode regions and individual primer pairs [27–30]. There are modifications to routine 
PCR protocols that address the particular problems of secondary metabolite PCR inhibitors from plant 
materials [43,44], and the effects of DNA degradation [35,36,45,46]. In all stages of the DNA 
barcoding process, it is good practice to include a positive control to ensure the quality of the 
procedure and troubleshoot problems. One example is described in the next section.  
The BP Nucleic Acid Reference Material (BPNARM) 
The intention of BP Appendix XI V [22] is to provide generic procedures for molecular identification 
of herbal drugs, whilst the Supplementary Chapter SC VII D. DNA Barcoding as a tool for Botanical 
Identification of Herbal Drugs [23] provides the information that differs between target samples, or 
species. To illustrate this, a worked example was published in the Appendix for Holy Basil [22]. This 
directs the user to the generic protocols where appropriate (e.g. DNA Extraction), and details the 
specific information for Holy Basil (e.g. DNA Purification, the Reference Sequence). As this was the 
first protocol to be published, information was given as to the primer sequence and PCR cycling 
parameters required for the trnH-psbA region.  
The Appendix method recommends that the efficiency of DNA extraction methods be confirmed, and 
that amplification protocols are controlled by the use of a known DNA sample. For this purpose the 
trnH-psbA BP Nucleic Acid Reference Material (BPNARM) was developed, which enables the user 
to confirm the suitability of their systems to conduct the analyses [47]. It is designed for use in two 
different ways: 
a. The BPNARM is mixed with the plant material prior to DNA extraction, and the product of this 
method is then a ‘co-extraction’ of both plant and BPNARM DNA. The recovery of the 
BPNARM DNA confirms that the extraction process has been conducted effectively, and the 
efficient amplification of this DNA indicates that PCR inhibitors are not preventing amplification.  
b. The BPNARM is used as a positive control for the PCR, demonstrating the suitability of the PCR 
reagents, experimental set up and amplicon detection method. 
The BPNARM was developed alongside the Holy Basil method, and Fig. 2 shows four examples of 
its application in troubleshooting: unsuccessful DNA extraction (Experiment 1), PCR inhibitors in the 
DNA samples (Experiment 2), demonstration of removal of PCR inhibitors by DNA purification 
(Experiment 3) and reduction of the effect of PCR inhibitors by dilution of the DNA template 
(Experiment 4). A detailed description of these experiments can be found in the Supporting 
Information.  This example demonstrates the value of using a known and reliable control substance 
the troubleshooting process can be much lengthier and technically demanding. 
The design of simple DNA tests for industrial quality control 
The scheme for DNA barcoding outlined in Fig. 1 is ideal for the identification of individual plant 
specimens. However, as indicated by the many recommended troubleshooting steps, Sanger 
sequencing of a DNA barcode region is not suited to routine, robust, high-throughput screening of 
dried and processed mixtures of sub-optimal plant tissue types containing degraded DNA. The authors 
have developed a strategy for industrial quality control that involves the design of simple, reliable, 
PCR tests that target individual differences in DNA barcode sequences [38,48,49] and only use DNA 
barcode sequencing as a confirmatory rather than routine assay for species authentication. These types 
of specific PCR assay targeting a short DNA barcode region have been developed by a number of 
authors [3–5,43]. The following section describes the development of such tests in an industrial 
setting, using Rhodiola rosea L. as an example.  
R. rosea root extract is a common medicinal plant in many countries used to stimulate the nervous 
system, decrease depression, enhance work performance, eliminate fatigue, and prevent high-altitude 
sickness thanks to its constituents such as salidroside (rhodioloside), rosavins, and p-tyrosol [50]. It 
grows in cold regions of the world, typically at high altitude on rocky outcrops, and is wild harvested 
in regions of Central Asia such as the Altai Mountains and the Qinghai-Tibetan Plateau [51–53]. A 
number of other Rhodiola species grow in similar arctic/alpine habitats, creating the potential for 
mistaken identity and nomenclature confusion as the roots are harvested and traded [52,54].  
Within an industrial quality control laboratory there are a number of tests used to confirm plant 
identity. The first stage is botanical morphology, both macroscopical and microscopical [8,17,18]. 
Further testing employs a range of analytical chemistry methods. TLC is one of the standard methods 
of pharmacopeia monographs. The technique is relatively simple and straightforward, and precision 
and standardisation has been improved by the development of HPTLC methods. (Fig. 4S shows an 
example of HPTLC analysis of R. rosea samples). One problem is that chemical markers used for 
identification have been found in similar species from the same genus, including Rhodiola rosea and 
related species [52]. Studies of commercially available products have also found that the species 
attribution is incorrect even though the target marker is detected [9]. Many herbal medicines are 
manufactured to contain a specified amount of certain chemical markers, as shown on the labelling. 
To ensure that a sample has the correct amount of marker, HPLC can be used to quantify the marker. 
The concentration of a certain marker can also be linked to the potential efficacy of a herbal medicine, 
as with rosavin, rosarin and rosin in Rhodiola rosea products [52] (Fig. 5S), and threshold 
concentrations are built into the quality control protocols. 
At the start of this study there were very few Rhodiola DNA barcode sequences available in the 
databases. Therefore, a reference collection of samples of ten different Rhodiola species was created. 
Genomic DNA was isolated and PCR amplification and DNA sequencing of four barcode loci (rbcl, 
trnH-psbA, matK and ITS) according to the scheme in Fig. 1 was successful for all the samples. 
Comparison of the four barcodes indicated that the ITS region would be the most suitable target for 
discrimination between R. rosea and other Rhodiola species in terms of the extent, nature and 
distribution of sequence variation through the barcode regions. The initial PCR assays were designed 
to these sequences along with a small number of accessions from GenBank.  
More recently, a large number of Rhodiola barcode sequences have been deposited in the database 
and a total of 438 ITS sequences from 36 Rhodiola species are now available (Table 2S). These 
sequences were used to:  
i. perform a retrospective confirmation of the reference collection specimens by constructing a 
phylogenetic tree from a multiple alignment of database and reference sequences, 
ii. check that the species-specific primers matched all instances of the target species and would not 
cross-react with any non-target species.  
This iterative confirmation of DNA test protocols is an important consequence of the accumulation of 
DNA sequences in the databases. 
In this example, PCR primers were designed to small (80-120bp) variable, species-discriminatory 
regions of the barcodes (Fig. 3). These are less vulnerable to DNA degradation and are ideal for 
quantitative real-time PCR (qPCR) analysis. The primary target was R. rosea, but primers for 
individual potential adulterant species and exclusive “non-rosea” primers were also designed. Generic 
primers were also designed to amplify any template DNA from the Rhodiola genus (Supporting 
Information, Fig. 3). As an illustration, Fig. 4d shows the results of conventional PCR tests with a pair 
of R. rosea-specific primers, giving a positive reaction only with the target template. A “non-rosea” 
primer pair amplified the other Rhodiola species but not R. rosea (Fig. 4c). The ITS (Fig. 4a) and 
generic primers (Fig. 4b) amplified all samples.  
The process from DNA extraction to gel imaging (Fig. 1), could be carried out in a basic molecular 
biology facility within 1 working day. However, qPCR is actually quicker and simpler to run than 
conventional PCR, since it does not require gel electrophoresis (with associated problems of 
reproducibility and gel image interpretation). The primer sets illustrated in Fig. 4 were tested using 
qPCR analysis after optimizing the thermocycling setting and primers concentrations. In this example, 
the amplification curves obtained using generic and rosea-specific primers are very similar when 
amplifying a R. rosea template (Fig. 5a). The near-identical Ct value between the two assay indicates 
a positive identification of the template as R. rosea, whereas the marked difference in Ct value 
(around 12 cycles) between the generic and specific primers using a panel of non-target species as the 
template (Fig. 5b) is a clear negative result (see Supporting Information for a detailed explanation).  
There are a number of strategies to improve the specificity of this type of PCR reaction, including the 
design of Amplification Refractory Mutation System (ARMS) primers with deliberately destabilised 
mismatch bases [43,56–58] and the use of Locked Nucleic Acid (LNA) primers to enhance specific 
primer binding [59,60].  
The importance of DNA method validation has been stressed by various authors [6,7,30,61]. In the 
Rhodiola study, around 40 R. rosea commercial samples were tested in parallel for rosavin content 
and by qPCR assay for R. rosea identification, with a small number of non-rosea samples as controls 
(see Supporting Information for details). The conclusions from this validation study were: 
1. The qPCR assay is rapid, robust and reliable. In theory, the 40 samples could be processed and 
analysed within one day. Correct identification results were obtained for all samples tested and 
were more reliable than the chemical tests. 
2. This type of test can be applied to samples where Sanger-based DNA barcoding would fail due to 
DNA degradation and mixed samples (see Figs. 1, 2). 
3. DNA tests are complementary to chemical assays – in this example, samples lacking the rosavin 
chemical markers would still be rejected, even if shown genetically to be the correct species. 
Conversely, a sample containing the correct chemical markers would be rejected if shown to be a 
substituted or adulterated species. 
The qPCR approach can also be used to quantify the amount of target DNA in a mixture, but this has 
limitations unless the precise nature of the adulterant is also known. It is much easier to distinguish 
between 0% and 2% contamination by a known adulterant, for example, than it is to determine that 
only 98% of a sample is the required target species.  
Another approach that has been more successful in this regard is High Resolution Melt curve analysis 
(HRM) [62,63] (more recently termed Bar-HRM when applied to species identification [64,65]). This 
technique can potentially discriminate between sequences containing a single base pair change and 
can detect the presence of both sequences in an admixture. Using Rhodiola as an illustration again, 
HRM primers were designed to conserved regions of the ITS sequences on either side of a short 
region of inter-specific variation, targeting species-specific single nucleotide polymorphisms (SNPs) 
(Supporting Information, Fig. 6S). A total of three different sets of primers were designed and tested 
against a reference panel of twelve Rhodiola species. All three set of primers could discriminate R. 
rosea samples from one of its most common contaminants, R. crenulata (Fig. 7S). When tested 
against all twelve Rhodiola species the primers were not uniquely specific for R. rosea, but could 
distinguish a number of variant types (Fig. 8S).  
Digital PCR offers the prospect of absolute quantitation of the number of starting template molecules 
in the PCR reaction by partition of each molecule into a separate compartment (on a chip or in an 
emulsion droplet) [66–68], and has been used for species authentication [4,69]. Because quantitation 
of the level of contamination by adulterants has proved to be a challenge for qPCR based assays, the 
aim is to determine whether the dPCR system can provide an authentication test capable of detecting 
contamination down to the required <2% foreign matter contamination threshold.  An example of the 
use of species-specific qPCR primers in a digital PCR (dPCR) system is shown in the Supporting 
Information (Fig. 9S).  
Prospects for next generation sequencing in industrial QC 
In recent years, DNA sequencing technology has made dramatic steps forward. The conventional 
Sanger method, where relatively short, targeted sequences are produced, is being replaced by so called 
next-generation sequencing (NGS) technologies, deploying high-throughput massively-parallel 
methods. NGS is based on a sequencing-by-synthesis approach along millions of single-stranded 
DNA templates, where each newly incorporated base produces a signal that is translated into a 
sequence. A major difference to Sanger sequencing is that every DNA fragment that is sequenced will 
result in an individual DNA output sequence (termed “read”), whereas in Sanger sequencing, the base 
call signal derives from numerous template molecules. 
Next-generation amplicon sequencing is the process of enriching a small DNA fragment of interest 
through PCR and simultaneously sequencing each of the resulting fragments. The major advantage 
over Sanger sequencing is that the sequence diversity of fragments from the PCR reaction is 
maintained in the reads. This technology has revolutionized the field of DNA metabarcoding, where 
mixed samples (e.g. environmental water samples [70]) are sequenced and analysed for species 
diversity by comparing the reads to a reference database [71]. The main concept of DNA barcoding is 
maintained by using common DNA barcodes that are flanked by universal primers. This concept has 
been successfully applied in pharmacovigilance and market studies of herbal medicinal products 
[1,2,5,72–74]. Here, an example of the application of these methods to commercial herbal products 
is described, using NGS sequencing and bioinformatics analysis to assess the composition of 
medicinal Phyllanthus amarus samples. The workflow of the analysis is summarised in Fig. 6. 
A library preparation method was designed that would enable four barcode regions to be sequenced 
for each of 44 DNA samples in one run, and the resulting data sorted. The workflow for amplicon 
sequencing needs to incorporate platform specific particularities: On Illumina platforms, the workflow 
includes two separate PCRs. In the first step, the trnH-psbA, ITS2, trnL-F and rbcL regions were 
amplified separately using standard amplification protocols and in the second step, a PCR with 
platform-specific adapters was applied to each sample. The samples were then pooled together and 
sequenced on an Illumina MiSeq instrument (Supporting Information). 
A major challenge of establishing standardised NGS protocols is to choose an appropriate and 
replicable bioinformatics pipeline. The bioinformatics pipeline applied in this study encompasses 
trimming of low quality reads, removal of optical duplicates and chimeric sequences and clustering of 
sequences that share 99% sequence similarity (for details see Supporting Information). The pipeline 
should ideally include a standardised procedure for storing data files and logs along with the analysis.  
As an example, the output from the NGS analysis of samples sold as Phyllanthus amarus is shown in 
Fig. 7. The abundance of sequence data produced and analysed lends itself to representation as a ‘heat 
map’. The more intense the blue colour, the greater the number of sequences matching to the species 
named in that row (see Supporting Information for a more detailed explanation). Our analysis 
suggests that many of the Phyllanthus samples are not pure and potentially intentionally substituted. 
Other studies draw similar conclusions when applying NGS amplicon sequencing to other herbal 
medicinal products [74-76]. However, a comprehensive benchmarking study that identifies acceptable 
levels of contamination and that investigates the limits of the method is lacking. 
 
The accuracy of the analysis depends the quality of the input library and the sequencing. Similar to 
Sanger sequencing, successful primer binding and amplification is crucial. The major source of errors 
in amplicon sequencing derives from PCR artefacts and sequencing errors which may in some cases 
difficult to detect in downstream analyses [77]. It is therefore highly recommended to use high-
fidelity polymerase enzymes with a minimal number of PCR cycles and to include quality control 
steps in the analysis pipeline. 
The reference database used to find the best match for DNA sequences is of fundamental importance, 
as is the case for all sequencing methods. This is of particular concern for NGS methods, as the 
number of reads generated makes meticulous analysis of all the sequences involved impossible. To 
some degree the number of sequences matched will dilute out any anomalous results, and a threshold 
of the number of matches required to assign any significance to a result can be incorporated. 
However, a fundamentally biased reference database, for example caused by a large study of one 
species within a genus, can make false positive identification an issue. Thus, a well maintained and 
comprehensive database containing a range of sister species and potential adulterant and substitute 
species is necessary. It should also be noted that detection to species level often depends on the 
discriminatory power of the barcode. The concept of the barcoding gap describes the distance between 
intra- and interspecific genetic variation. The assumption is that a barcoding gap exists, when the 
intraspecific genetic distance of the barcode is smaller than the interspecific distance [78]. A careful 




The choice of barcode locus is also constrained by the length of the region. The read length derived 
from next-generation sequencers is smaller than the sequences from Sanger sequencing and thus the 
discriminatory power is potentially smaller. Whereas Sanger methods can produce reads of >1000bp, 
NGS methods can sequence up to 300bp from either end of an amplicon. This produces 600bp of 
sequence data once the reads have been paired, including primers and binding regions, so ~ 550bp of 
sample sequence data. This means that longer barcode regions are problematic to analyse, for instance 
matK and the full nrITS. Use of the shorter ITS2 region instead of the nrITS can circumvent this 
limitation for this region, but there is currently no universal shorter matK region.  
NGS is a major forward step for molecular methods, and allows an extremely high level analysis of 
any sample. However, the amount of data generated by this method also requires that it is analysed 
using specialised bioinformatics programs, and by highly skilled individuals. The lack of skilled 
bioinformaticians has been highlighted and is being addressed by universities and researchers, but 
remains a limitation of NGS methods. Another issue is the access to NGS equipment. Although the 
cost per read for this method is actually much lower than for Sanger methods, the price of equipment 
and consumables is not easily accessible for those starting out in molecular methods. The use of 
external companies to conduct the final few steps in the procedure, and also some of the data analysis, 
is widespread and many companies offer this service.  
Conclusion  
Despite reservations about the application of DNA testing to herbal medicine authentication, industry 
is adopting DNA quality control tests in response to two drivers: the increased confidence in the 
identity of the herbal material and compliance with regulatory requirements (as exemplified by the 
British Pharmacopoeia) that the techniques can bring, and the potential cost saving of utilising 
inexpensive, high-throughput tests for authentication of plant raw materials (as exemplified by the 
Rhodiola rosea tests). Although phytopharmaceutical quality control infrastructure and expertise has 
historically been largely based around analytical chemistry, the introduction of molecular biological 
testing is relatively straightforward and is gradually being taken up by the industry. Whilst 
conventional DNA barcoding by Sanger sequencing is not ideal for rapid, robust quality testing, it 
does provide considerable genetic information upon which to base simpler DNA based tests for 
industrial QC. 
NGS is a powerful tool for the molecular analysis of herbals; it provides a depth to the analysis and a 
direct identification of the target species. The area where NGS is unrivalled is in identifying unknown 
or unexpected species that are present as adulterants or contaminants to the ‘headline’ species. Sanger 
sequencing can mask the presence of additional species, as the results generated are based on calling 
each base from a large number of amplicons simultaneously. NGS methods allow each contributing 
species to be identified individually, within one sample. These results can also be semi-quantitative, 
providing some measure of the proportion of each species in a sample (although biases in the PCR 
process prevent this from being absolute). 
While this method shows the promise to answer all the possible requirements of industry, the barriers 
in terms of cost and expertise required currently place it firmly in the ‘future prospects’ category, 
when laboratory teams have perfected methods to make it accessible and cost effective. 
  
Supporting Information 
Five examples of the authors unpublished work have been used to illustrate this review. These are: 
Example 1. The British Pharmacopoeia DNA based identification method for Ocimum tenuiflorum; 
Example 2. The BP Nucleic Acid Reference Material (BPNARM); Example 3.  A specific qPCR 
assay for Rhodiola rosea; Example 4.  A High Resolution Melt curve assay for Rhodiola species; 
Example 5.  NGS assay of Phyllanthus samples. The experimental details (Materials and Methods, 
and Results) for each example are included as Supporting Information.  
There are two supporting tables: 
Table 1S Commercial “Holy Basil” samples used for development of the British Pharmacopoeia DNA 
based identification method for Ocimum tenuiflorum; Table 2S. Rhodiola ITS sequences used in this 
study. 
There are ten supporting figures: 
Fig. 1S. Multiple alignment of trnH-psbA region sequences from Holy Basil commercial samples; 
Fig. 2S. Bases 190-260 of a multiple alignment of trnH-psbA region sequences from Holy Basil 
commercial samples; Fig. 3S. Bases 300-370 of a multiple alignment of trnH-psbA region sequences 
from Holy Basil commercial samples; Fig. 4S. HPTLC of Rhodiola samples and reference 
compounds; Fig. 5S. HPLC trace of an extract from Rhodiola rosea, showing the presence of the 
rosavine marker compounds: rosarin, rosavin and rosin; Fig. 6S. Two Rhodiola ITS regions selected 
for HRM curve analysis primers design; Fig. 7S. HRM curve analysis results using the HRM1, HRM2 
and HRM3 primer pairs with R. rosea and R. crenulata templates; Fig. 8S. HRM curve analysis 
results using the HRM1, HRM2 and HRM3 primer pairs with 11 different Rhodiola templates; Fig. 
9S. Clarity digital PCR results with species-specific primers; Fig. 10S. Representation of the 
constructs produced for NGS barcoding. 
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Figure Legends 
Fig. 1. DNA barcoding flowchart. The chart indicates the steps involved in a normal DNA barcoding 
workflow, with quality control decision points to ensure positive outcomes and troubleshoot 
problematic steps in the process. 
Fig. 2. The use of a standardised positive control for DNA extraction and PCR troubleshooting. 
Experiment 1. Results from an unsuccessful DNA extraction. Experiment 2. Effect of inhibitors 
present in the DNA samples. Experiment 3. Effect of removal of inhibitors from DNA samples, 
demonstrating that all inhibitors had now been removed from the DNA samples. Experiment 4. 
Effect of dilution of purified DNA. In each experiment the samples are: DNA sample, DNA extracted 
from plant material; DNA co-extraction, DNA extracted from plant material mixed with the trnH-
psbA BPNARM; Positive PCR control, PCR using the trnH-psbA BPNARM as template; Negative 
control, PCR with molecular grade water added in place of a DNA template. (Experimental details in 
Supporting Information.) 
Fig. 3. Fragment of a multiple alignment of the ITS region from a selection of Rhodiola species 
(GQ374187 R. rosea; AB088600 R. ishidae; AY359892 R. crenulata; KF113690 R. coccinea; 
KF113719 R. sacra). The highlighted sections show variable (left) and conserved (right) regions 
where species-specific and generic primers could be designed, respectively. 
Fig. 4. Agarose gel electrophoresis of PCRs using a) ITS primers; b) generic Rhodiola primers; c) 
non-rosea primers; d) R. rosea-specific primers (Experimental details in Supporting Information). 
Gel lanes: 1. R. pachyclados; 2. R. rosea; 3. R. heterodontha; 4. R. saxifragoides; 5. R. crenulata; 6. 
Negative (no template) control. The sizes of the bands were confirmed by DNA sequencing. 
Fig. 5. Quantitative RT-PCR assay to distinguish a) Rhodiola rosea and b) adulterants. The assay is 
based on the difference in Ct (threshold cycle) between generic and specific primers. Similar Ct  
values indicate a positive identification (a), whilst a marked rightward shift in the specific primer Ct 
value indicates a negative result (b). (Experimental details in Supporting Information) 
Fig. 6. Overview of the bioinformatics pipeline for NGS data analysis. 
Fig. 7. Heat map showing the number of sequences matching to different species in the NCBI 
database for each of 14 samples. The intensity of the colour represents the number of matches, shown 
on the scale. The categories shown on the y axis are species where the sequence in the database is 
only present for that species. Where a sequence matches to more than one species in the genus, the 
genus is listed as the category. Three DNA samples were analysed for each of samples 1-13, four 
DNA extracts for sample 14; each of these is shown independently (Experimental details in 
Supporting Information). 
